Trial
NCT03311126
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Wisconsin, Madison
Collaborators
Genentech, Inc.
Condition
Mantle Cell Lymphoma
Intervention
Bendamustine
Why stopped
slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-24